Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Nature Medicine2007Vol. 13(9), pp. 1050–1059
Citations Over TimeTop 1% of 2007 papers
Lionel Apétoh, François Ghiringhelli, Antoine Tesnière, Michel Obéid, Carla Ortiz, Alfredo Criollo, Grégoire Mignot, Maria Chiara Maiuri, Evelyn Ullrich, Patrick Saulnier, Huan Yang, Sebastián Amigorena, Bernard Ryffel, Franck J. Barrat, Paul Säftig, Françis Lévi, Rosette Lidereau, Catherine Noguès, Jean‐Paul Mira, Agnès Chompret, V. Joulin, Françoise Clavel‐Chapelon, Jean Bourhis, Fabrice André, Suzette Delaloge, Thomas Tursz, Guido Kroemer, Laurence Zitvogel
Related Papers
- → The HMGB1–TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis(2013)138 cited
- → Toll-like Receptor 4 (TLR4) Antagonist Eritoran Tetrasodium Attenuates Liver Ischemia and Reperfusion Injury through Inhibition of High-Mobility Group Box Protein B1 (HMGB1) Signaling(2014)77 cited
- → Potential anti-inflammatory effect of anti-HMGB1 in animal models of ICH by downregulating the TLR4 signaling pathway and regulating the inflammatory cytokines along with increasing HO1 and NRF2(2021)7 cited
- → Toll-like receptor 4 (TLR4) and interferon-gamma (IFN-r) are required for HMGB1-induced TNF release from macrophages. (34.18)(2010)1 cited
- → The time related concentration of serum HMGB1 and TLR4 in CLP rat model(2018)